Journals / Turkish Neurosurgery / 2009 / Cilt: 19 - Sayı: 3

Siklooksijenaz inhibitörlerinin 6-hidroksidopamin ile oluşturulan deneysel parkinson modelinde nöroprotektif etkilerinin araştırılması

Investigation of neuroprotective effects of cyclooxygenase inhibitors in the 6-hydroxydopamine induced rat parkinson model

Pages
230–236
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: Oral usage of low repeated doses of nonsteroidal anti–inflammatory drugs may possibly slow down the progression of the disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: Recent experimental and clinical studies on Parkinson's disease point out the pivotal role of inflammation in the pathogenesis of neurodegeneration and the possible positive effects of nonsteroidal anti-inflammatory drug therapies.
📊
Key Findings & Data:Our aim in this study was to investigate the preventive effects of nonsteroidal anti–inflammatory drugs in the 6–hydroxydopamine (6-OHDA) induced rat model of Parkinson's disease.
💡
Conclusion & Impact:CONCLUSION: Oral usage of low repeated doses of nonsteroidal anti–inflammatory drugs may possibly slow down the progression of the disease.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

AIM: Recent experimental and clinical studies on Parkinson's disease point out the pivotal role of inflammation in the pathogenesis of neurodegeneration and the possible positive effects of nonsteroidal anti-inflammatory drug therapies. Our aim in this study was to investigate the preventive effects of nonsteroidal anti–inflammatory drugs in the 6–hydroxydopamine (6-OHDA) induced rat model of Parkinson's disease. MATERIAL and METHODS: Twenty-one female Wistar-Albino rats (200-250g) were used in this study. The rats were divided in three groups: Saline group (n: 7, 2 ml), Acetylsalicylic acid group (n: 7, 100 mg/kg), and Meloxicam group (n: 7, 50 mg/kg). An hour after administration, the rats received a unilateral intranigral injection of 6-OHDA to produce the Parkinson model lesion. Rotational tests were performed two weeks later as follow-up. Immunohistochemical tests were performed in all groups to determine the severity of the lesion in the substantia nigra. RESULTS: Administration of drugs an hour before the lesions were created did not protect the degeneration of dopaminergic neurons in the substantia nigra. CONCLUSION: Oral usage of low repeated doses of nonsteroidal anti–inflammatory drugs may possibly slow down the progression of the disease.

Özet

AMAÇ: Parkinson Hastalığı, bazal ganglionların substantia nigra bölgesindeki dopaminerjik nöronların ölümüyle karakterize dejeneratif bir bozukluktur. Sayıları giderek artan deneysel ve klinik çalışmalar, nörodejeneratif bu hastalığın patogenezinde inflamasyonun rolü ve non-steroid antiinflamatuar ilaçların koruyucu etkilerinin rolünü araştırmayı amaçlamaktadır. Bu amaçla NSAİİ'ların 6-OHDA ile oluşturulmuş sıçan Parkinson modelindeki koruyucu etkileri araştırıldı. YÖNTEM ve GEREÇ: Çalışmada, 200-250 g ağırlığında 21 adet dişi Wistar-Albino cinsi sıçan kullanıldı. Rastgele gruplara ayrılan sıçanlara enteral yolla serum fizyolojik, asetil salisilik asit ve meloksikam uygulandı. Bu uygulamadan bir saat sonra sıçanlara Parkinson modelini oluşturmak için intranigral olarak tek taraflı 6-hidroksidopamin enjeksiyonu gerçekleştirildi. Bu enjeksiyondan iki hafta sonra da sıçanlarda Parkinson modeli oluşup oluşmadığını gözlemek için dönme testleri uygulandı. Substantia nigra bölgesindeki lezyonun gösterilebilmesi için immünohistokimyasal testler kullanıldı. BULGULAR: Çalışmamızda, bu ilaçların lezyondan bir saat önce uygulanması, substantia nigra bölgesindeki dopaminerjik nöronları dejenerasyondan korumamıştır. SONUÇ: Bu çalışmada, NSAİİ'ların akut tek doz kullanılması dejenerasyonu önlemese bile, oral yolla uzun süreli tekrarlayan kullanımları bu hastalığın ilerlemesini yavaşlatabilir.

🔖

Cite This Article

GÖREN, B., MİMBAY, Z., BİLİCİ, N., ZARİFOĞLU, M., OĞUL, E., KORFALI, E. (2009). Siklooksijenaz inhibitörlerinin 6-hidroksidopamin ile oluşturulan deneysel parkinson modelinde nöroprotektif etkilerinin araştırılması. Turkish Neurosurgery, Cilt: 19 - Sayı: 3, 230–236. https://ajindex.com/articles/405211

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Aubin N, Curet O, Deffois A, Carter C: Aspirin and salicylate Protect against MPTP-induced dopamine depletion in mice. J Neurochem 71:1635-1642, 1998 2. Bezzi P, Volterra A: A neuron-glia signalling network in the active brain. Curr Opin Neurobiol 11:387-394, 2001 3. Di Matteo V, Pierucci M, Di Giovanni G, Di Santo A, Poggi A, Benigno A, Esposito E: Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: An in vivo microdialysis study. Brain Res 1095(1):167-177, 2006 4. Di Matteo V, Benigno A, Pierucci M, Giuliano DA, Crescimanno G, Esposito E, Di Giovanni G: 7-Nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration - An in vivo microdialysis study. Ann N Y Acad Sci 1089:462-471, 2006 5. Ferger B, Teismann P, Earl CD, Kuschinsky K, Oertel WH: Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch Pharmacol 360:256-261, 1999 6. Gao HM, Liu B, Zhang WQ, Hong JS: Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP Model of Parkinson's Disease. Faseb Journal 17, 2003 7. Grilli M, Pizzi M, Memo M, Spano P: Neuroprotection by Aspirin and sodium salicylate through blockade of NF-Kappa B activation. Science 274:1383-1385, 1996 8. Hirsch EC: Glial cells and Parkinson's Disease. J Neurol 247 Suppl 2:II58-II62, 2000 9. Klivenyi P, Gardian G, Calingasan NY, Yang LC, Beal MF: Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Mol Neurosci 21(3):191-198, 2003 10. Kopp E, Ghosh S: Inhibition of Nf-Kappa-B by sodiumsalicylate and Aspirin. Science 265:956-959, 1994 11. Kurkowska-Jastrzebska I, Babiuch M, Joniec I, Przybylkowski A, Czlonkowski A, Czlonkowska A: Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. Int Immunopharmacol 2(8):1213-1218, 2002 12. Liu B, Gao HM, Hong JS: Parkinson's Disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: Role of neuroinflammation. Environ Health Perspect, 111:1065-1173, 2003 13. Maharaj DS, Saravanan KS, Maharaj H, Mohanakumar KP, Daya S: Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Neuroc